ReviewFrontiers in pharmacology2026
From multi-target mechanisms to clinical translation: the analgesic potential of quercetin.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Large-scale comparative virtual screening identifies novel molecular targets underlying the multi-target activity of quercetin in psoriasis.Inflammopharmacology · 2026Article
- A comprehensive review of ischemic heart disease: pathophysiology, current treatments, natural products-based therapies, and nanotherapeutics.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a major global health challenge, pain often eludes optimal management by current therapies due to limitations like side effects and inadequate efficacy in certain subtypes. Quercetin, a natural flavonoid, has emerged as a promising broad-spectrum analgesic, demonstrating efficacy in diverse pain models including inflammatory, neuropathic, and cancer-related pain. This review systematically delineates the broad-spectrum analgesic efficacy of quercetin across diverse pain conditions, including inflammatory, neuropathic, cancer, and postoperative pain. We comprehensively dissect its sophisticated molecular mechanisms, encompassing the suppression of neuroinflammation via modulating glial cell activation and polarization, the mitigation of oxidative stress and ferroptosis, the regulation of key ion channels and neuroreceptors, and the restoration of neural pathway homeostasis. Furthermore, we discuss innovative drug delivery strategies designed to overcome quercetin's pharmacokinetic limitations and enhance its therapeutic potential. Despite promising preclinical results, challenges in clinical translation, particularly regarding bioavailability and the need for robust clinical validation, are critically examined. By integrating the latest preclinical and clinical evidence and providing a pain-centric, mechanism-driven analytical framework, this review addresses the critical gap in dedicated research on quercetin's analgesic properties and offers a novel theoretical basis for the rational development of quercetin-based therapeutic strategies for clinical pain management. This study consolidates evidence on quercetin's analgesic pharmacology and translational potential, concluding that it represents a viable multi-target candidate, with future research poised to optimize its formulations and validate clinical efficacy for pain management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.